FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083792010> ?p ?o ?g. }

• W2083792010 endingPage "1209" @default.
• W2083792010 startingPage "1202" @default.
• W2083792010 abstract "BACKGROUND Using a specific monoclonal antibody (MAb), B-B4, coupled to bismuth-213 (213Bi) by a chelating agent (CITC-DTPA), the feasibility of alpha-radioimmunotherapy (RIT) for multiple myeloma (MM) has been demonstrated previously. METHODS In this study, the two MAbs tested, MA5 and B-B4, target the epithelial antigens Muc-1 and syndecan-1, respectively, which are both expressed by MM cell lines. Antibody characterization was evaluated by flow cytometric analysis of normal and tumoral hematopoeitic cells of MM patients as well as immunohistochemical tests of normal, nonhematopoetic tissues. Radiobiologic effects were evaluated for 213Bi- and iodine-131 (131I)–labeled antibodies. We assessed in vitro mortality (thymidine incorporation, MTT, and clonogenic assays) and cell cycle modifications with propidium iodide staining. These tests were performed on MM cell lines until 120 hours postirradiation at several time points, using radiolabeled antibody concentrations ranging from 0.5 to 20 nM and specific activities ranging from 240 to 1200 MBq/mg of MAb. RESULTS MA5 stained all MM cells in only 50% of patients, whereas B-B4 recognized all MM cells in all patients. B-B4 principally showed hepatic, pulmonary, and duodenal staining, whereas MA5 marked renal and pulmonary tissues. RIT with 213Bi-B-B4 induced specific mortality and G2/M phase cell cycle arrest, which depended on the concentrations and specific activity. For 213Bi-MA5, this arrest appeared at concentrations above 10 nM, an amount fivefold higher than that required with B-B4. This difference was also found in thymidine incorporation assays. Furthermore, with 213Bi-B-B4, the arrest at the G2/M phase appeared quickly, within 24 hours after irradiation, and affected up to 60% of the cells (for 20 nM of 213Bi-B-B4 at 1,200 MBq/mg). Conversly, 131I-B-B4 had a very limited effect on cell mortality and did not induce any cell cycle arrest. CONCLUSIONS The results of this study show that B-B4 might be the more effective therapeutic antibody and suggest that alpha-RIT might be more suitable than beta-RIT for treating single-cell tumor models. Thus, these findings set the stage for the beginning of clinical trials using alpha-emitter–radiolabeled B-B4, with special attention paid to hepatic, pulmonary, and intestinal side effects. Cancer 2002;94:1202–9. © 2002 American Cancer Society. DOI 10.1002/cncr.10286" @default.
• W2083792010 created "2016-06-24" @default.
• W2083792010 creator A5002836262 @default.
• W2083792010 creator A5018500231 @default.
• W2083792010 creator A5021098221 @default.
• W2083792010 creator A5028847161 @default.
• W2083792010 creator A5031144079 @default.
• W2083792010 creator A5042347658 @default.
• W2083792010 creator A5058532201 @default.
• W2083792010 creator A5064802518 @default.
• W2083792010 creator A5077540798 @default.
• W2083792010 date "2002-02-12" @default.
• W2083792010 modified "2023-10-18" @default.
• W2083792010 title "Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma" @default.
• W2083792010 cites W1554322881 @default.
• W2083792010 cites W1973288508 @default.
• W2083792010 cites W1977833865 @default.
• W2083792010 cites W1987527069 @default.
• W2083792010 cites W1991787503 @default.
• W2083792010 cites W2002025776 @default.
• W2083792010 cites W2013137776 @default.
• W2083792010 cites W2023189156 @default.
• W2083792010 cites W2031429783 @default.
• W2083792010 cites W2036754489 @default.
• W2083792010 cites W2075383063 @default.
• W2083792010 cites W2080585386 @default.
• W2083792010 cites W2084493022 @default.
• W2083792010 cites W2091016446 @default.
• W2083792010 cites W2092695916 @default.
• W2083792010 cites W2094250974 @default.
• W2083792010 cites W2113319880 @default.
• W2083792010 cites W2316160054 @default.
• W2083792010 cites W2326596666 @default.
• W2083792010 cites W2340762582 @default.
• W2083792010 cites W2615655254 @default.
• W2083792010 cites W3145716452 @default.
• W2083792010 cites W4238509480 @default.
• W2083792010 cites W42909849 @default.
• W2083792010 doi "https://doi.org/10.1002/cncr.10286" @default.
• W2083792010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11877746" @default.
• W2083792010 hasPublicationYear "2002" @default.
• W2083792010 type Work @default.
• W2083792010 sameAs 2083792010 @default.
• W2083792010 citedByCount "63" @default.
• W2083792010 countsByYear W20837920102012 @default.
• W2083792010 countsByYear W20837920102013 @default.
• W2083792010 countsByYear W20837920102014 @default.
• W2083792010 countsByYear W20837920102015 @default.
• W2083792010 countsByYear W20837920102016 @default.
• W2083792010 countsByYear W20837920102017 @default.
• W2083792010 countsByYear W20837920102018 @default.
• W2083792010 countsByYear W20837920102019 @default.
• W2083792010 countsByYear W20837920102020 @default.
• W2083792010 countsByYear W20837920102022 @default.
• W2083792010 countsByYear W20837920102023 @default.
• W2083792010 crossrefType "journal-article" @default.
• W2083792010 hasAuthorship W2083792010A5002836262 @default.
• W2083792010 hasAuthorship W2083792010A5018500231 @default.
• W2083792010 hasAuthorship W2083792010A5021098221 @default.
• W2083792010 hasAuthorship W2083792010A5028847161 @default.
• W2083792010 hasAuthorship W2083792010A5031144079 @default.
• W2083792010 hasAuthorship W2083792010A5042347658 @default.
• W2083792010 hasAuthorship W2083792010A5058532201 @default.
• W2083792010 hasAuthorship W2083792010A5064802518 @default.
• W2083792010 hasAuthorship W2083792010A5077540798 @default.
• W2083792010 hasBestOaLocation W20837920101 @default.
• W2083792010 hasConcept C117262875 @default.
• W2083792010 hasConcept C142724271 @default.
• W2083792010 hasConcept C159654299 @default.
• W2083792010 hasConcept C190283241 @default.
• W2083792010 hasConcept C202751555 @default.
• W2083792010 hasConcept C203014093 @default.
• W2083792010 hasConcept C2775934118 @default.
• W2083792010 hasConcept C2776146153 @default.
• W2083792010 hasConcept C2776364478 @default.
• W2083792010 hasConcept C31573885 @default.
• W2083792010 hasConcept C542903549 @default.
• W2083792010 hasConcept C55493867 @default.
• W2083792010 hasConcept C71924100 @default.
• W2083792010 hasConcept C86803240 @default.
• W2083792010 hasConceptScore W2083792010C117262875 @default.
• W2083792010 hasConceptScore W2083792010C142724271 @default.
• W2083792010 hasConceptScore W2083792010C159654299 @default.
• W2083792010 hasConceptScore W2083792010C190283241 @default.
• W2083792010 hasConceptScore W2083792010C202751555 @default.
• W2083792010 hasConceptScore W2083792010C203014093 @default.
• W2083792010 hasConceptScore W2083792010C2775934118 @default.
• W2083792010 hasConceptScore W2083792010C2776146153 @default.
• W2083792010 hasConceptScore W2083792010C2776364478 @default.
• W2083792010 hasConceptScore W2083792010C31573885 @default.
• W2083792010 hasConceptScore W2083792010C542903549 @default.
• W2083792010 hasConceptScore W2083792010C55493867 @default.
• W2083792010 hasConceptScore W2083792010C71924100 @default.
• W2083792010 hasConceptScore W2083792010C86803240 @default.
• W2083792010 hasIssue "S4" @default.
• W2083792010 hasLocation W20837920101 @default.
• W2083792010 hasLocation W20837920102 @default.
• W2083792010 hasOpenAccess W2083792010 @default.

• next